Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates

Dae Hun Kim, Byung Woo Jhun, Seong Mi Moon, Su-Young Kim, Kyeongman Jeon, O Jung Kwon, Hee Jae Huh, Nam Yong Lee, Sung Jae Shin, Charles L. Daley, Won-Jung Koh
Dae Hun Kim
aDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Byung Woo Jhun
aDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seong Mi Moon
aDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Su-Young Kim
aDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyeongman Jeon
aDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O Jung Kwon
aDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hee Jae Huh
bDepartment of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nam Yong Lee
bDepartment of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sung Jae Shin
cDepartment of Microbiology, Yonsei University College of Medicine, Seoul, South Korea
dInstitute for Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, South Korea
eBrain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles L. Daley
fDivision of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado, USA
gDepartment of Medicine, University of Colorado, Aurora, Colorado, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Won-Jung Koh
aDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00665-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

We evaluated the in vitro activities of the antimicrobial drugs bedaquiline and delamanid against the major pathogenic nontuberculous mycobacteria (NTM). Delamanid showed high MIC values for all NTM except Mycobacterium kansasii. However, bedaquiline showed low MIC values for the major pathogenic NTM, including Mycobacterium avium complex, Mycobacterium abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. kansasii. Bedaquiline also had low MIC values with macrolide-resistant NTM strains and warrants further investigation as a potential antibiotic for NTM treatment.

INTRODUCTION

The incidence and prevalence of pulmonary disease (PD) associated with nontuberculous mycobacteria (NTM) are increasing worldwide (1, 2). Mycobacterium avium complex (MAC), Mycobacterium abscessus, and Mycobacterium kansasii are the most common pathogens for NTM PD worldwide (3–5). Macrolide antibiotics, such as clarithromycin and azithromycin, are key drugs for treating NTM PD, especially MAC PD (1, 2). Treatment outcomes are still not satisfactory (6–9), however, and the development of acquired resistance to macrolides can further worsen treatment outcomes (10, 11). Moreover, M. abscessus isolates can have intrinsic inducible macrolide resistance or acquired macrolide resistance, and M. abscessus PD is the most difficult-to-treat type of NTM PD (12–14). Therefore, discovery of new and repurposed drugs is urgently needed (15).

Bedaquiline and delamanid are new drugs for the treatment of multidrug-resistant tuberculosis (16–20). Bedaquiline is a diarylquinoline that inhibits the proton pump of mycobacterial ATP synthase, and delamanid is a compound derived from nitrodihydroimidazooxazole that inhibits mycolic acid synthesis (21–23). Previous studies reported that the MICs of bedaquiline and delamanid for Mycobacterium tuberculosis, including multidrug-resistant isolates, were very low (24, 25).

Recently, the MICs of bedaquiline against MAC, including M. avium and Mycobacterium intracellulare, have been reported (26–28). In those studies, most macrolide-sensitive MAC isolates showed low MICs for bedaquiline (26–28). In addition, M. abscessus subsp. abscessus and M. abscessus subsp. massiliense have low MIC values for bedaquiline (28–30).

In contrast to those bedaquiline studies, there has been only one study on the MICs of delamanid for MAC (31), and delamanid MICs for other NTM species have not been reported. In addition, there has been no comparative analysis of MIC values for bedaquiline and delamanid with various NTM, including macrolide-resistant NTM. The purpose of the present study was to evaluate the MICs of bedaquiline and delamanid against major pathogenic NTM clinical isolates, including macrolide-resistant NTM.

For this study, which was initially approved by the institutional review board (IRB) of Samsung Medical Center in 2008 and has received IRB approval once a year (IRB approval no. 2008-09-016; last updated 2 February 2019), we included 251 clinical isolates of five major pathogenic NTM (M. avium, M. intracellulare, M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. kansasii) isolated from patients newly diagnosed with NTM PD. We also included 56 clinical isolates of acquired-macrolide-resistant NTM (M. avium, M. intracellulare, M. abscessus subsp. abscessus, and M. abscessus subsp. massiliense), which were confirmed to have a 23S rRNA gene mutation associated with the acquisition of macrolide resistance (32–34). In vitro susceptibility testing with bedaquiline and delamanid was performed by measuring the MIC using the broth microdilution method, according to Clinical and Laboratory Standards Institute guidelines (35). Mycobacterium peregrinum ATCC 700686, M. abscessus ATCC 19977, M. avium ATCC 700898, and M. kansasii ATCC 12478 were used as controls.

Table 1 shows the MIC, MIC50, and MIC90 values of bedaquiline and delamanid for 251 isolates from newly diagnosed NTM PD patients. All MAC, M. abscessus subsp. massiliense, and M. kansasii isolates were susceptible to macrolides; most M. abscessus subsp. abscessus isolates, except for 11 macrolide-susceptible isolates, had inducible resistance to macrolides, which was confirmed using sequence analysis of the erm(41) gene. MAC and M. kansasii isolates had very low bedaquiline MIC50 (≤0.016 μg/ml) and MIC90 (≤0.016 μg/ml) values. Although the M. abscessus subsp. abscessus and M. abscessus subsp. massiliense isolates also had very low bedaquiline MIC50 (0.062 μg/ml) and MIC90 (0.125 μg/ml) values, the MICs were higher than those for MAC and M. kansasii isolates.

View this table:
  • View inline
  • View popup
TABLE 1

MIC ranges and MIC50 and MIC90 values of bedaquiline and delamanid for 251 clinical NTM isolates

In contrast, MAC, M. abscessus subsp. abscessus, and M. abscessus subsp. massiliense isolates had very high delamanid MIC50 (8 to >16 μg/ml) and MIC90 (>16 μg/ml) values. Compared to those NTM, M. kansasii had relatively low delamanid MIC50 (0.25 μg/ml) and MIC90 (1 μg/ml) values.

The MIC, MIC50, and MIC90 values for bedaquiline and delamanid with 56 isolates of macrolide-resistant NTM are shown in Table 2. All macrolide-resistant NTM isolates showed very low bedaquiline MIC50 (≤0.016 to 0.062 μg/ml) and MIC90 (≤0.016 to 0.25 μg/ml) values. For all macrolide-resistant NTM isolates, however, the delamanid MIC50 (4 to >16 μg/ml) and MIC90 (>16 μg/ml) values were very high (Table 2).

View this table:
  • View inline
  • View popup
TABLE 2

MIC ranges and MIC50 and MIC90 values of bedaquiline and delamanid for 56 macrolide-resistant clinical NTM isolates

In this study, we evaluated the bedaquiline and delamanid MICs for major pathogenic NTM clinical isolates, including acquired-macrolide-resistant NTM isolates. Consistent with previous studies, our results showed that MAC, M. abscessus subsp. abscessus, and M. abscessus subsp. massiliense isolates, as well as M. kansasii isolates, had low bedaquiline MIC50 and MIC90 values.

In particular, the low bedaquiline MICs for macrolide-resistant NTM isolates, including MAC, M. abscessus subsp. abscessus, and M. abscessus subsp. massiliense isolates, are notable in this study. Although the clarithromycin MIC50 and MIC90 values for all macrolide-resistant NTM isolates were >64 μg/ml, the macrolide-resistant NTM isolates showed significantly lower bedaquiline MIC50 (≤0.016 to 0.062 μg/ml) and MIC90 (≤0.016 to 0.25 μg/ml) values. These results suggest that bedaquiline may be an effective antimicrobial for treatment of macrolide-resistant NTM strains.

In contrast, in this study, the delamanid MICs were high for most major pathogenic NTM isolates. The exception was M. kansasii, for which the delamanid MIC50 and MIC90 values were relatively low, compared to the values for other NTM isolates. These results, especially the delamanid MICs for MAC isolates, differed from those of one previous study (31). Although studies on delamanid resistance have reported that five genes (ddn, fgd1, fbiA, fbiB, and fbiC) are associated with delamanid resistance in M. tuberculosis (36), a similar association has not yet been reported for NTM. Given the high delamanid MICs that we observed with MAC and M. abscessus clinical isolates, additional studies to identify genes that contribute to delamanid resistance in NTM are needed.

Previous studies reported that mutations within the atpE, Rv0678, and pepQ genes are involved in bedaquiline resistance in M. tuberculosis (37). In addition, recent studies on bedaquiline-resistance-related genes in NTM have been reported. Alexander and colleagues found that mutations in the mmpT5 and atpE genes were associated with bedaquiline resistance in MAC strains (38). In addition, in M. abscessus subsp. abscessus, mutations in the atpE and MAB_2299c genes have been reported to be associated with bedaquiline resistance (39, 40). Therefore, if bedaquiline is used for NTM treatment, then the possibility of bedaquiline resistance due to mutation in a bedaquiline-resistance-related gene should be considered, although most NTM isolates had very low bedaquiline MIC values in this study.

In summary, we evaluated the in vitro activities of bedaquiline and delamanid against major pathogenic NTM clinical isolates. Our results showed that bedaquiline had good in vitro activity against major pathogenic NTM but delamanid did not. Bedaquiline has the potential to be a potent agent for the treatment of NTM PD, including macrolide-resistant NTM PD.

ACKNOWLEDGMENTS

This research was supported by the National Research Foundation of Korea (NRF), funded by the South Korean Ministry of Science, Information, and Communications Technologies (grant NRF-2018R1A2A1A05018309 to W.-J.K.), and by the Basic Science Research Program through the NRF, funded by the Ministry of Education (grant NRF-2016R1A6A3A11930738 to D.H.K.).

C.L.D. has received grants from Insmed, Inc., and served on advisory boards for Otsuka, Insmed, Johnson and Johnson, Spero, and Horizon, not associated with the submitted work. W.-J.K. has received a consultation fee from Insmed, Inc., for the Insmed advisory board meeting, not associated with the submitted work. Otherwise, we have no conflicts of interest to declare.

FOOTNOTES

    • Received 28 March 2019.
    • Returned for modification 23 April 2019.
    • Accepted 4 June 2019.
    • Accepted manuscript posted online 10 June 2019.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Griffith DE,
    2. Aksamit T,
    3. Brown-Elliott BA,
    4. Catanzaro A,
    5. Daley C,
    6. Gordin F,
    7. Holland SM,
    8. Horsburgh R,
    9. Huitt G,
    10. Iademarco MF,
    11. Iseman M,
    12. Olivier K,
    13. Ruoss S,
    14. von Reyn CF,
    15. Wallace RJ, Jr,
    16. Winthrop K
    . 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367–416. doi:10.1164/rccm.200604-571ST.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Haworth CS,
    2. Banks J,
    3. Capstick T,
    4. Fisher AJ,
    5. Gorsuch T,
    6. Laurenson IF,
    7. Leitch A,
    8. Loebinger MR,
    9. Milburn HJ,
    10. Nightingale M,
    11. Ormerod P,
    12. Shingadia D,
    13. Smith D,
    14. Whitehead N,
    15. Wilson R,
    16. Floto RA
    . 2017. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72(Suppl 2):ii1–ii64. doi:10.1136/thoraxjnl-2017-210927.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Stout JE,
    2. Koh WJ,
    3. Yew WW
    . 2016. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis 45:123–134. doi:10.1016/j.ijid.2016.03.006.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Adjemian J,
    2. Daniel-Wayman S,
    3. Ricotta E,
    4. Prevots DR
    . 2018. Epidemiology of nontuberculous mycobacteriosis. Semin Respir Crit Care Med 39:325–335. doi:10.1055/s-0038-1651491.
    OpenUrlCrossRef
  5. 5.↵
    1. Kwon YS,
    2. Koh WJ
    . 2016. Diagnosis and treatment of nontuberculous mycobacterial lung disease. J Korean Med Sci 31:649–659. doi:10.3346/jkms.2016.31.5.649.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Pasipanodya JG,
    2. Ogbonna D,
    3. Deshpande D,
    4. Srivastava S,
    5. Gumbo T
    . 2017. Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease. J Antimicrob Chemother 72(Suppl 2):i3–i19. doi:10.1093/jac/dkx311.
    OpenUrlCrossRef
  7. 7.↵
    1. Kwak N,
    2. Park J,
    3. Kim E,
    4. Lee CH,
    5. Han SK,
    6. Yim JJ
    . 2017. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis 65:1077–1084. doi:10.1093/cid/cix517.
    OpenUrlCrossRef
  8. 8.↵
    1. Diel R,
    2. Nienhaus A,
    3. Ringshausen FC,
    4. Richter E,
    5. Welte T,
    6. Rabe KF,
    7. Loddenkemper R
    . 2018. Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review. Chest 153:888–921. doi:10.1016/j.chest.2018.01.024.
    OpenUrlCrossRef
  9. 9.↵
    1. Koh WJ,
    2. Moon SM,
    3. Kim SY,
    4. Woo MA,
    5. Kim S,
    6. Jhun BW,
    7. Park HY,
    8. Jeon K,
    9. Huh HJ,
    10. Ki CS,
    11. Lee NY,
    12. Chung MJ,
    13. Lee KS,
    14. Shin SJ,
    15. Daley CL,
    16. Kim H,
    17. Kwon OJ
    . 2017. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J 50:1602503. doi:10.1183/13993003.02503-2016.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Griffith DE
    . 2018. Treatment of Mycobacterium avium complex (MAC). Semin Respir Crit Care Med 39:351–361. doi:10.1055/s-0038-1660472.
    OpenUrlCrossRef
  11. 11.↵
    1. Kwon YS,
    2. Koh WJ,
    3. Daley CL
    . 2019. Treatment of Mycobacterium avium complex pulmonary disease. Tuberc Respir Dis 82:15–26. doi:10.4046/trd.2018.0060.
    OpenUrlCrossRef
  12. 12.↵
    1. Koh WJ,
    2. Jeong BH,
    3. Kim SY,
    4. Jeon K,
    5. Park KU,
    6. Jhun BW,
    7. Lee H,
    8. Park HY,
    9. Kim DH,
    10. Huh HJ,
    11. Ki CS,
    12. Lee NY,
    13. Kim HK,
    14. Choi YS,
    15. Kim J,
    16. Lee SH,
    17. Kim CK,
    18. Shin SJ,
    19. Daley CL,
    20. Kim H,
    21. Kwon OJ
    . 2017. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis 64:309–316. doi:10.1093/cid/ciw724.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Koh WJ,
    2. Stout JE,
    3. Yew WW
    . 2014. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. Int J Tuber Lung Dis 18:1141–1148. doi:10.5588/ijtld.14.0134.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Strnad L,
    2. Winthrop KL
    . 2018. Treatment of Mycobacterium abscessus complex. Semin Respir Crit Care Med 39:362–376. doi:10.1055/s-0038-1651494.
    OpenUrlCrossRef
  15. 15.↵
    1. Wu ML,
    2. Aziz DB,
    3. Dartois V,
    4. Dick T
    . 2018. NTM drug discovery: status, gaps and the way forward. Drug Discov Today 23:1502–1519. doi:10.1016/j.drudis.2018.04.001.
    OpenUrlCrossRef
  16. 16.↵
    1. Ahmad N,
    2. Ahuja SD,
    3. Akkerman OW,
    4. Alffenaar JC,
    5. Anderson LF,
    6. Baghaei P,
    7. Bang D,
    8. Barry PM,
    9. Bastos ML,
    10. Behera D,
    11. Benedetti A,
    12. Bisson GP,
    13. Boeree MJ,
    14. Bonnet M,
    15. Brode SK,
    16. Brust JCM,
    17. Cai Y,
    18. Caumes E,
    19. Cegielski JP,
    20. Centis R,
    21. Chan PC,
    22. Chan ED,
    23. Chang KC,
    24. Charles M,
    25. Cirule A,
    26. Dalcolmo MP,
    27. D'Ambrosio L,
    28. de Vries G,
    29. Dheda K,
    30. Esmail A,
    31. Flood J,
    32. Fox GJ,
    33. Frechet-Jachym M,
    34. Fregona G,
    35. Gayoso R,
    36. Gegia M,
    37. Gler MT,
    38. Gu S,
    39. Guglielmetti L,
    40. Holtz TH,
    41. Hughes J,
    42. Isaakidis P,
    43. Jarlsberg L,
    44. Kempker RR,
    45. Keshavjee S,
    46. Khan FA,
    47. Kipiani M,
    48. Koenig SP,
    49. Koh WJ,
    50. Kritski A,
    51. Kuksa L,
    52. Kvasnovsky CL,
    53. Kwak N,
    54. Lan Z,
    55. Lange C,
    56. Laniado-Laborin R,
    57. Lee M,
    58. Leimane V,
    59. Leung CC,
    60. Leung EC,
    61. Li PZ,
    62. Lowenthal P,
    63. Maciel EL,
    64. Marks SM,
    65. Mase S,
    66. Mbuagbaw L,
    67. Migliori GB,
    68. Milanov V,
    69. Miller AC,
    70. Mitnick CD,
    71. Modongo C,
    72. Mohr E,
    73. Monedero I,
    74. Nahid P,
    75. Ndjeka N,
    76. O'Donnell MR,
    77. Padayatchi N,
    78. Palmero D,
    79. Pape JW,
    80. Podewils LJ,
    81. Reynolds I,
    82. Riekstina V,
    83. Robert J,
    84. Rodriguez M,
    85. Seaworth B,
    86. Seung KJ,
    87. Schnippel K,
    88. Shim TS,
    89. Singla R,
    90. Smith SE,
    91. Sotgiu G,
    92. Sukhbaatar G,
    93. Tabarsi P,
    94. Tiberi S,
    95. Trajman A,
    96. Trieu L,
    97. Udwadia ZF,
    98. van der Werf TS,
    99. Veziris N,
    100. Viiklepp P,
    101. Vilbrun SC,
    102. Walsh K,
    103. Westenhouse J,
    104. Yew WW,
    105. Yim JJ,
    106. Zetola NM,
    107. Zignol M,
    108. Menzies D
    . 2018. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 392:821–834. doi:10.1016/S0140-6736(18)31644-1.
    OpenUrlCrossRef
  17. 17.↵
    1. Schnippel K,
    2. Ndjeka N,
    3. Maartens G,
    4. Meintjes G,
    5. Master I,
    6. Ismail N,
    7. Hughes J,
    8. Ferreira H,
    9. Padanilam X,
    10. Romero R,
    11. Te Riele J,
    12. Conradie F
    . 2018. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 6:699–706. doi:10.1016/S2213-2600(18)30235-2.
    OpenUrlCrossRef
  18. 18.↵
    1. Ndjeka N,
    2. Schnippel K,
    3. Master I,
    4. Meintjes G,
    5. Maartens G,
    6. Romero R,
    7. Padanilam X,
    8. Enwerem M,
    9. Chotoo S,
    10. Singh N,
    11. Hughes J,
    12. Variava E,
    13. Ferreira H,
    14. Te Riele J,
    15. Ismail N,
    16. Mohr E,
    17. Bantubani N,
    18. Conradie F
    . 2018. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J 52:1801528. doi:10.1183/13993003.01528-2018.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Kim CT,
    2. Kim TO,
    3. Shin HJ,
    4. Ko YC,
    5. Hun Choe Y,
    6. Kim HR,
    7. Kwon YS
    . 2018. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea. Eur Respir J 51:1702467. doi:10.1183/13993003.02467-2017.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Mok J,
    2. Kang H,
    3. Hwang SH,
    4. Park JS,
    5. Kang B,
    6. Lee T,
    7. Koh WJ,
    8. Yim JJ,
    9. Jeon D
    . 2018. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea. J Antimicrob Chemother 73:503–508. doi:10.1093/jac/dkx373.
    OpenUrlCrossRef
  21. 21.↵
    1. Andries K,
    2. Verhasselt P,
    3. Guillemont J,
    4. Gohlmann HW,
    5. Neefs JM,
    6. Winkler H,
    7. Van Gestel J,
    8. Timmerman P,
    9. Zhu M,
    10. Lee E,
    11. Williams P,
    12. de Chaffoy D,
    13. Huitric E,
    14. Hoffner S,
    15. Cambau E,
    16. Truffot-Pernot C,
    17. Lounis N,
    18. Jarlier V
    . 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223–227. doi:10.1126/science.1106753.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Matsumoto M,
    2. Hashizume H,
    3. Tomishige T,
    4. Kawasaki M,
    5. Tsubouchi H,
    6. Sasaki H,
    7. Shimokawa Y,
    8. Komatsu M
    . 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466. doi:10.1371/journal.pmed.0030466.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Kwon YS,
    2. Koh WJ
    . 2016. Synthetic investigational new drugs for the treatment of tuberculosis. Expert Opin Investig Drugs 25:183–193. doi:10.1517/13543784.2016.1121993.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Pang Y,
    2. Zong Z,
    3. Huo F,
    4. Jing W,
    5. Ma Y,
    6. Dong L,
    7. Li Y,
    8. Zhao L,
    9. Fu Y,
    10. Huang H
    . 2017. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother 61:e00900-17. doi:10.1128/aac.00900-17.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Lopez B,
    2. Siqueira de Oliveira R,
    3. Pinhata JMW,
    4. Chimara E,
    5. Pacheco Ascencio E,
    6. Puyen Guerra ZM,
    7. Wainmayer I,
    8. Simboli N,
    9. Del Granado M,
    10. Palomino JC,
    11. Ritacco V,
    12. Martin A
    . 2019. Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region. J Antimicrob Chemother 74:373–379. doi:10.1093/jac/dky414.
    OpenUrlCrossRef
  26. 26.↵
    1. Brown-Elliott BA,
    2. Philley JV,
    3. Griffith DE,
    4. Thakkar F,
    5. Wallace RJ, Jr
    . 2017. In vitro susceptibility testing of bedaquiline against Mycobacterium avium complex. Antimicrob Agents Chemother 61:e01798-16. doi:10.1128/AAC.01798-16.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Vesenbeckh S,
    2. Schonfeld N,
    3. Krieger D,
    4. Bettermann G,
    5. Bauer TT,
    6. Russmann H,
    7. Mauch H
    . 2017. Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections. Eur Respir J 49:1601969. doi:10.1183/13993003.01969-2016.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Pang Y,
    2. Zheng H,
    3. Tan Y,
    4. Song Y,
    5. Zhao Y
    . 2017. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother 61:e02627-16. doi:10.1128/AAC.02627-16.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Li B,
    2. Ye M,
    3. Guo Q,
    4. Zhang Z,
    5. Yang S,
    6. Ma W,
    7. Yu F,
    8. Chu H
    . 2018. Determination of MIC distribution and mechanisms of decreased susceptibility to bedaquiline among clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother 62:e00175-18. doi:10.1128/AAC.00175-18.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Brown-Elliott BA,
    2. Wallace RJ, Jr
    . 2019. In vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex. Antimicrob Agents Chemother 63:e01919-18. doi:10.1128/aac.01919-18.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Krieger D,
    2. Schonfeld N,
    3. Vesenbeckh S,
    4. Bettermann G,
    5. Bauer TT,
    6. Russmann H,
    7. Mauch H
    . 2016. Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? Eur Respir J 48:1803–1804. doi:10.1183/13993003.01420-2016.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Moon SM,
    2. Park HY,
    3. Kim SY,
    4. Jhun BW,
    5. Lee H,
    6. Jeon K,
    7. Kim DH,
    8. Huh HJ,
    9. Ki CS,
    10. Lee NY,
    11. Kim HK,
    12. Choi YS,
    13. Kim J,
    14. Lee SH,
    15. Kim CK,
    16. Shin SJ,
    17. Daley CL,
    18. Koh WJ
    . 2016. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease. Antimicrob Agents Chemother 60:6758–6765. doi:10.1128/AAC.01240-16.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Choi H,
    2. Kim SY,
    3. Kim DH,
    4. Huh HJ,
    5. Ki CS,
    6. Lee NY,
    7. Lee SH,
    8. Shin S,
    9. Shin SJ,
    10. Daley CL,
    11. Koh WJ
    . 2017. Clinical characteristics and treatment outcomes of patients with acquired macrolide-resistant Mycobacterium abscessus lung disease. Antimicrob Agents Chemother 61:e01146-17. doi:10.1128/AAC.01146-17.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Choi H,
    2. Kim SY,
    3. Lee H,
    4. Jhun BW,
    5. Park HY,
    6. Jeon K,
    7. Kim DH,
    8. Huh HJ,
    9. Ki CS,
    10. Lee NY,
    11. Lee SH,
    12. Shin SJ,
    13. Daley CL,
    14. Koh WJ
    . 2017. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium massiliense lung disease. Antimicrob Agents Chemother 61:e02189-16. doi:10.1128/AAC.02189-16.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    Clinical Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard—2nd ed. CLSI document M24-A2. Clinical Laboratory Standards Institute, Wayne, PA.
  36. 36.↵
    1. Fujiwara M,
    2. Kawasaki M,
    3. Hariguchi N,
    4. Liu Y,
    5. Matsumoto M
    . 2018. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis (Edinb) 108:186–194. doi:10.1016/j.tube.2017.12.006.
    OpenUrlCrossRef
  37. 37.↵
    1. Nguyen TVA,
    2. Anthony RM,
    3. Banuls AL,
    4. Nguyen TVA,
    5. Vu DH,
    6. Alffenaar JC
    . 2018. Bedaquiline resistance: its emergence, mechanism, and prevention. Clin Infect Dis 66:1625–1630. doi:10.1093/cid/cix992.
    OpenUrlCrossRef
  38. 38.↵
    1. Alexander DC,
    2. Vasireddy R,
    3. Vasireddy S,
    4. Philley JV,
    5. Brown-Elliott BA,
    6. Perry BJ,
    7. Griffith DE,
    8. Benwill JL,
    9. Cameron AD,
    10. Wallace RJ, Jr
    . 2017. Emergence of mmpT5 variants during bedaquiline treatment of Mycobacterium intracellulare lung disease. J Clin Microbiol 55:574–584. doi:10.1128/JCM.02087-16.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Dupont C,
    2. Viljoen A,
    3. Thomas S,
    4. Roquet-Baneres F,
    5. Herrmann JL,
    6. Pethe K,
    7. Kremer L
    . 2017. Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus and is effective in infected zebrafish. Antimicrob Agents Chemother 61:e01225-17. doi:10.1128/AAC.01225-17.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Richard M,
    2. Gutierrez AV,
    3. Viljoen A,
    4. Rodriguez-Rincon D,
    5. Roquet-Baneres F,
    6. Blaise M,
    7. Everall I,
    8. Parkhill J,
    9. Floto RA,
    10. Kremer L
    . 2019. Mutations in the MAB_2299c TetR regulator confer cross-resistance to clofazimine and bedaquiline in Mycobacterium abscessus. Antimicrob Agents Chemother 63:e01316-18. doi:10.1128/AAC.01316-18.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates
Dae Hun Kim, Byung Woo Jhun, Seong Mi Moon, Su-Young Kim, Kyeongman Jeon, O Jung Kwon, Hee Jae Huh, Nam Yong Lee, Sung Jae Shin, Charles L. Daley, Won-Jung Koh
Antimicrobial Agents and Chemotherapy Jul 2019, 63 (8) e00665-19; DOI: 10.1128/AAC.00665-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates
Dae Hun Kim, Byung Woo Jhun, Seong Mi Moon, Su-Young Kim, Kyeongman Jeon, O Jung Kwon, Hee Jae Huh, Nam Yong Lee, Sung Jae Shin, Charles L. Daley, Won-Jung Koh
Antimicrobial Agents and Chemotherapy Jul 2019, 63 (8) e00665-19; DOI: 10.1128/AAC.00665-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Mycobacterium abscessus
Mycobacterium avium complex
Mycobacterium kansasii
bedaquiline
delamanid
nontuberculous mycobacteria

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596